Le porte-parole canadien
de la biotechnologie
Nos membres
| Location: |
Ottawa, Ontario |
| Industry Sector: |
Professional Services and Consulting |
| Website: |
3sixtypublicaffairs.com/ |
| Contact: |
Blake Johnston (wdempster@3sixtypublicaffairs.com)
1 613 8008340
|
| Description: |
3Sixty is a government relations and public policy consulting firm based in Ottawa, Canada, serving the agri-food, consumer products, health and life sciences sectors. The company strive to bridge differences between how governments, stakeholders and businesses communicate and make decisions. Drawing on business and government experience, 3Sixty provides industry-leading advice and counsel with integrity, commitment and top-notch client service. |
| Location: |
Saint-Laurent, Quebec |
| Industry Sector: |
Pharma |
| Website: |
abbott.ca |
| Contact: |
Tina Ventura (tina.ventura@abbott.com)
1 514 8327000
|
| Ownership: |
Subsidiary - : |
| Description: |
Abbott Laboratories is an American global pharmaceuticals and health care products company. Abbott Canada is an affiliate of Abbott Laboratories. |
| Location: |
Saskatoon, Saskatchewan |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.adetherapeutics.com |
| Contact: |
Sanj Singh (info@adetherapeutics.com)
1 306 2615189
|
| Description: |
AdeTherapeutics is a privately-held clinical-stage drug development company. The company's vision is to be leader in developing products that deal with complications related to surgery. AdeTherapeutics has a robust portfolio of high value products by developing clinical-stage ready therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages (i.e. Phase II trials). Lead indication is in adhesion prevention in gyne and general surgery in Phase 1/2 trial. Additional products are in neurosurgery, cosmetic surgery and wound care. |
| Location: |
Washington, D.C., District Of Columbia |
| Industry Sector: |
Professional Services and Consulting |
| Website: |
www.adjuvant.com |
| Contact: |
Jeff Conroy (jxc@adjuvant.com)
1 301 8306290
|
| Description: |
Adjuvant Partners is a life sciences transaction advisory company representing a portfolio of small-mid cap firms with clinical and pre-clincial programs in regenerative medicine and other advanced biotherapeutics. Many of our clients are working with stem cells in either therapeutic applications or drug discovery. Primary indications include cardiovascular disease, neuro-degenerative disorders, wound healing, cancer, and a number of orhpan indications. Our team has experience working in successful public and start-up firms in the life science, healthcare, and technology markets. We have a unique perspective of today's markets and trends, which has enabled us to identify unmet needs, invigorate established products, create profitable alliances, and launch new ventures. |
| Location: |
Toronto, Massachusetts |
| Industry Sector: |
Pharma |
| Website: |
www.afnm.com |
| Contact: |
Ed Mascioli (oroberts@afnm.com)
1 416 6456614
|
| Description: |
Affinium is a specialty pharmaceutical company developing a new class of antibiotics based on Fatty Acid Synthesis (FASI) Inhibition. Affinium's antibacterial programs constitute a new antibiotic platform with the potential for multiple products. |
| Location: |
Ottawa, Ontario |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.aic.ca |
| Contact: |
Frances Rodenburg (frodenburg@aic.ca)
1 613 2329459
|
| Description: |
The Agricultural Institute of Canada exists to build scientific capacity for the sustainable and profitable optimization of societal benefits that can be derived from the agro-economy. The agro-economy consists of all knowledge chains (from basic and applied research to innovation, commercialization and technology transfer) and all value chains that rely upon or focus upon agricultural output as a major input to final products. |
| Location: |
Ottawa, Ontario |
| Industry Sector: |
Biotechnology - other |
| Website: |
www.agrisoma.com |
| Contact: |
Steven F. Fabijanski (sfabijanski@agrisoma.com)
1 613 8345265
|
| Description: |
Agrisoma Biosciences Inc. is a private agricultural biotechnology company using its edge ETL technology to create new crop varieties engineered for high-value applications such as biofuel production. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.aimtherapeutics.com |
| Contact: |
Frank Gleeson (fgleeson@aimtherapeutics.com)
1 647 237 3691
|
| Description: |
AIM is a drug development company focused on respiratory diseases. They are developing a novel class of patented non-steroidal, immune modulating drug candidates which exhibit potent anti-inflammatory effects and a favourable safety profile in numerous animal models of disease. |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.alethiabio.com |
| Contact: |
Yves Cornellier (info@alethiabio.com)
1 514 858 7666
|
| Description: |
Alethia Biotherapeutics is engaged in the discovery of novel targets and development of targeted therapeutics. The company has prioritized the development of monoclonal antibodies against novel clinically relevant targets identified using its STAR target discovery platform. |
| Location: |
Cheshire, Connecticut |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.alxn.com |
| Contact: |
Leonard Bell
1 203 2722596
|
| Ownership: |
Public - NASDAQ: ALXN |
| Description: |
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products |
| Location: |
Vancouver, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.allontherapeutics.com |
| Contact: |
(info@allontherapeutics.com)
1 604 7360634
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): NPC.TO |
| Description: |
Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to market innovative central nervous system therapies. Allon’s lead drug, davunetide, is proceeding in a fully enrolled pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP), under a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA). This pivotal trial is based upon statistically significant human efficacy demonstrated in amnestic mild cognitive impairment, cognitive impairment associated with schizophrenia, and positive biomarker data. |
| Location: |
San Clemente, California |
| Industry Sector: |
Medical Technology |
| Website: |
www.alturainc.com |
| Contact: |
Leslie Hamer (lhamer@alturainc.com)
1 949 2735050
|
| Description: |
Altura Medical, Inc. is an early stage medical device manufacturer. They are focused on devices and methods for the treatment of aneurysms in the arterial vascular system. |
| Location: |
Mississauga, Ontario |
| Industry Sector: |
Pharma |
| Website: |
www.amgen.ca |
| Contact: |
Natasha Bond (natashab@amgen.com)
1 905 2853000
|
| Ownership: |
Subsidiary - : |
| Description: |
Amgen Canada applies science and innovation to help fight serious illness and dramatically improve people's lives. Amgen contributes to the development of new therapies or new uses for existing medicines in partnership with many of Canada's leading healthcare, academic, research, government, and patient organizations. |
| Location: |
Mississauga, Ontario |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.amorfix.com/ |
| Contact: |
Robert Gundel (bob.gundel@amorfix.com)
1 416 8476898
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): AMF |
| Description: |
Amorfix Life Sciences Ltd. (TSX:AMF) is a product development company creating therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's disease (AD), cancer and ALS. Amorfix utilizes it computational discovery platform, ProMIS, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS and AD diagnostic tests. In addition, Amorfix's proprietary Epitope Protection technology enables the specific identification and mearurement of very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation, and development of a predictive screening test for AD. |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.angiochem.com |
| Contact: |
Catherine Gagnon (info@angiochem.com)
1 514 7887800
|
| Description: |
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates (PDC) that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new PDCs have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB. Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including brain cancer, neurodegenerative and lysosomal storage diseases, pain, and others. |
| Location: |
St. John's, Newfoundland |
| Industry Sector: |
Biotechnology - other |
| Website: |
www.aquabounty.com |
| Contact: |
David A. Frank (investors@aquabounty.com)
1 709 738-4638
|
| Ownership: |
Subsidiary - : |
| Description: |
Aqua Bounty Technologies is a biotechnology company focused on improving productivity in commercial aquaculture. |
| Location: |
Richmond, British Columbia |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.aqxpharma.com |
| Contact: |
Kamran Alam (info@aqxpharma.com)
1 604 629 9223
|
| Description: |
Aquinox Pharmaceuticals is a private, venture-backed biopharmaceutical company committed to the discovery, development and commercialization of novel and targeted small molecule therapeutics for the treatment of inflammatory disease and cancer. The lead clinical candidate, AQX-1125, is a highly active and selective small molecule allosteric activator of SHIP1 suitable for once-daily oral dosing as a pill. |
| Location: |
Quebec, Quebec |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.asmacure.com |
| Contact: |
Martin J. Driscoll (martin.driscoll@asmacure.com)
1 418 780 4255
|
| Description: |
Asmacure Ltée is focused on the development of nicotinic receptor modulators for the treatment of inflammatory diseases. Their lead compound, ASM-024, is the first nicotinic receptor modulator to enter clinical testing for the treatment of asthma. |
| Location: |
Mississauga, Ontario |
| Industry Sector: |
Pharma |
| Website: |
www.astrazeneca.ca |
| Contact: |
Nicklas Westerholm (IR@astrazeneca.com)
1 905 277 7111
|
| Ownership: |
Subsidiary - : |
| Description: |
AstraZeneca Canada is an operating subsidiary of a global research based pharmaceutical company. Currently they are most interested in talking with companies that have products that are in pre-registration, registered and/or currently marketed. |
| Location: |
North Vancouver, British Columbia |
| Industry Sector: |
Medical Technology |
| Website: |
www.augurex.com |
| Contact: |
Norma K. Biln
1 778 839 3319
|
| Description: |
Augurex Life Sciences Corp. develops biomarkers, which are substances that indicate what is going on in the body, thereby making them useful for diagnosing and managing patients’ diseases through the use of simple blood tests. |
| Location: |
Malvern, Victoria |
| Industry Sector: |
Public / Non-Profit Organizations |
| Website: |
www.ausbiotech.org |
| Contact: |
Anna Lavelle (admin@ausbiotech.org)
61 3 98281404
|
| Description: |
AusBiotech is Australia's biotechnology industry organisation, which represents over 3,000 members, covering the human health, agricultural, medical device, bioinformatics, environmental and industrial sectors in biotechnology. AusBiotech is dedicated to the development, growth and prosperity of the Australian Biotechnology Industry, by providing initiatives to drive sustainability and growth, outreach and access to markets, and representation and support for members nationally and around the world. AusBiotech has representation in each Australian state providing a national network to support members and promote the commercialisation of Australian bioscience in the national and international marketplaces. Their membership base includes biotechnology companies, ranging from start-ups to mature multinationals, research institutes and universities, specialist service professionals, corporate, institutional, individual and student members from Australia and overseas. |
| Location: |
Ottawa, Ontario |
| Industry Sector: |
Biotechnology - other |
| Website: |
www.chemaphor.com |
| Contact: |
Graham Burton (g.burton@chemaphor.com)
1 613 9498164
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): CFR.V |
| Description: |
Chemaphor Inc. is an Ottawa-based biotechnology company operating in the animal and human health markets. Its proprietary products are designed to provide improvements in health for pets and, eventually, humans. At this stage of its development, the Company only has animal-related products. |
| Location: |
Montreal, Quebec |
| Industry Sector: |
Investor |
| Website: |
www.bdc.ca |
| Contact: |
Paul Kirkconnell (info@bdc.ca)
|
| Description: |
BDC Venture Capital is a major venture capital investor in Canada, active at every stage of the company's development cycle, from seed through expansion, with a focus on technology-based businesses that have high growth potential and that are positioned to become dominant players in their markets. |
| Location: |
Laval, Quebec |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
www.bellushealth.com |
| Contact: |
Tony Matzouranis (tmatzouranis@bellushealth.com)
1 450 6804500
|
| Ownership: |
Public - Toronto Stock Exchange (TSX): BLU.TO |
| Description: |
BELLUS Health is a publicly-traded biotechnology company focused on the treatment of amyloid-related diseases with clear unmet medical need, such as Alzheimer's disease and AA Amyloidosis. |
| Location: |
Toronto, Ontario |
| Industry Sector: |
Professional Services and Consulting |
| Website: |
www.belmorelaw.com |
| Contact: |
Neil McWilliams (info@belmorelaw.com)
1 416 863 1771
|
| Description: |
Belmore McIntosh Neidrauer LLP is a dynamic intellectual property law firm that excels at close working relationships with North American and international clients. Company also offer guidance and opinions in non-contentious areas of intellectual property including assisting companies in developing their technologies, in-licensing and in due diligence issues. |
